CK
CKDXF.US Opthea Ltd
- Market cap
- USD 14.6M
- P/E
- 0.1x
- P/B
- 0.72x
- ROE
- 1,076.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CKDXF.US undervalued?
Graham numberThe Graham number of Opthea Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Opthea Ltd fundamental analysis
No fundamental analysis for Opthea Ltd yet.
Opthea Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Opthea Ltd
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was i…
Full company profileOpthea Ltd financial statements
Opthea Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 74.9K | 145K | 112K | 146K | 92.0K | 125K | 108K | 125K | 25.4K | 667.30 |
| Gross Profit | -26.6K | -28.7K | -161K | -371K | -360K | -107K | -89.3K | 22.0K | -67.0K | 667.30 |
| Operating Income | -9.90M | -31.9M | -36.7M | -24.5M | -39.6M | -96.5M | -150M | -192M | -156M | -7.97M |
| EBITDA | -9.80M | -29.7M | -36.6M | -24.6M | -50.1M | -99.0M | -134M | -199M | -123M | -8.26M |
| Net Income | -6.19M | -16.9M | -20.9M | -16.4M | -60.8M | -128M | -212M | -220M | -163M | 221M |
| EPS | -0.03 | -0.07 | -0.09 | -0.06 | -0.18 | -0.34 | -0.45 | -0.35 | -0.13 | 0.16 |
| Balance Sheet | ||||||||||
| Total Assets | 56.5M | 46.1M | 37.7M | 71.9M | 184M | 87.3M | 148M | 189M | 56.8M | 22.1M |
| Total Liabilities | 2.05M | 7.90M | 6.54M | 7.08M | 4.16M | 17.6M | 157M | 265M | 258M | 1.60M |
| Shareholders' Equity | 54.5M | 38.2M | 31.1M | 64.8M | 180M | 69.8M | -8.79M | -75.8M | -201M | 20.5M |
| Cash & Short-term Investments | 52.0M | 32.5M | 21.5M | 62.0M | 118M | 44.6M | 134M | 172M | 48.4M | 20.8M |
| Total Debt | - | - | - | 265K | 113K | - | 85.8M | 142M | 248M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -6.05M | -19.9M | -24.2M | -8.72M | -45.5M | -71.3M | -121M | -161M | -159M | -8.65M |
| Capital Expenditure | 3.08K | 34.4K | 18.1K | 3.67K | 17.0K | 23.3K | 32.6K | 33.5K | 13.0K | 0.00 |
| Free Cash Flow | -6.05M | -20.0M | -24.2M | -8.25M | -61.1M | -98.4M | -179M | -161M | -159M | -8.65M |
| Ratios | ||||||||||
| ROE | -11.4% | -44.3% | -67.2% | -25.3% | -33.7% | -183.4% | - | - | - | 1,076.3% |
| ROA | -11.0% | -36.7% | -55.5% | -22.8% | -33.0% | -146.6% | -143.0% | -116.7% | -286.6% | 998.2% |
| Net Profit Margin | -8,272.6% | -11,650.4% | -18,587.2% | -11,255.2% | -66,087.6% | -102,353.7% | -196,185.8% | -176,665.7% | -641,313.4% | 33,044,499.9% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Opthea Ltd dividends
Opthea Ltd has not paid dividends in the last 10 fiscal years.
Last stock split: 53:50 on Nov 14, 2023.
Who owns Opthea Ltd
- Insiders 35.43%
- Institutions 4.30%
- Public & others 60.27%
- Shares outstanding 1.37B
- Free float 772M
Opthea Ltd company profile
- Company name
- Opthea Ltd
- Ticker
- CKDXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- June
- Address
- 117 Camberwell Road, Hawthorn East, VIC, Australia, 3123
- Phone
- 61 3 9826 0399
- Website
- ceryvyn.com
About Opthea Ltd
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.
Opthea Ltd management
6- Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.Executive Chair & CEO · born 1953
- Mr. Hamish GeorgeCFO & Joint Company Secretary
- Dr. Stuart MudgeChief Operating Officer
- Dr. Michael Gerometta Ph.D.Chief Technology Officer · born 1964
- Ms. Rebbecca WilcoxSenior VP of Preclinical and Translational Science
- Ms. Stephanie VipondJoint Company Secretary